The total economic burden of Sanfilippo syndrome in the U.S. is on track to exceed $2 billion in the…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
A bone marrow transplant may help improve motor function in children with Sanfilippo syndrome, according to a new study…
The case of a 44-year-old woman who was diagnosed with Sanfilippo syndrome type A co-occurring with a heart abnormality…
The U.S. Food and Drug Administration (FDA) is requesting changes to Ultragenyx Pharmaceutical’s manufacturing process before it will consider…
Ultragenyx Pharmaceutical’s experimental gene therapy UX111 slows or halts the brain damage that affects communication and cognitive and motor…
GC1130A, an experimental enzyme replacement therapy (ERT) for Sanfilippo syndrome type A, has been put on the fast track…
Over the next two decades, the economic burden of Sanfilippo syndrome in the U.S. is expected to exceed $2…
Most children with Sanfilippo syndrome type A who received the one-time gene therapy UX111 early in life in a clinical…
Standardized tests that measure memory, motor function, and well-being can be used to track the progression of neurological dysfunction in…
JCR Pharmaceuticals has won permission from officials in Germany to start a Phase 1/2 clinical trial of JR-441, an…